A highly potent bispecific antibody confers complete protection against SFTSV in preclinical models.
A bispecific antibody combining nanobodies N2C1 and N2D2 provides complete protection against SFTSV in ferret models at low doses and late treatment times.
- Why it matters: SFTSV causes severe disease with up to 30% fatality, and no effective licensed treatments are available, highlighting the urgent need for potent therapeutics.
- What they did: Researchers identified two nanobodies that neutralize SFTSV by targeting different domains of the viral glycoprotein, then engineered a bispecific antibody that showed enhanced potency in preclinical models.
- The result: The bispecific antibody achieved full protection in ferrets even when administered two days after infection, paving the way for its development as a promising clinical candidate.